{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:36:59Z","timestamp":1773797819475,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Psychotropics are increasingly used in pediatrics, often as off-label medicines. The guarantees of safety and efficacy are not always granted in clinical practice compared to adult authorised indications. A retrospective observational study was done to estimate the prevalence of psychotropic use in pediatric subjects of Catalonia (Spain). Anonymised data on dispensation of psychotropics to pediatric patients, demography and other related data were obtained by the local healthcare management for the period 2008\u20132017. Estimation of off-label use was done through description of drug dispensations with no authorised use related to age range. The prevalence of psychotropics was 40.8\u201364.2 per 1,000 pediatric inhabitants. Hydroxyzine-only represented two-thirds of dispensations, and when removed, the prevalence dropped to 26.4\u201332.2 per 1,000 pediatric inhabitants. Adolescents and boys were more likely to receive a psychotropic. Psychostimulants had the highest exposure rate, mainly due to methylphenidate. Off-label use was observed in 12% of subjects, corresponding to 4.6% of all dispensed psychotropics with boys being more exposed. The proportion of off-label use vs. labelled use was higher in younger populations. Aripiprazole had the highest off-label frequency. Our data support the frequent reality of off-label use in pediatrics, despite the potential underestimation related to the selected off-label definition. There is an urgent need to systematically ascertain effectiveness and any potential adverse events in the off-label pediatric setting, and to generate valuable information for risk-benefit assessment in these populations where extrapolation from adults is not reliable.<\/jats:p>","DOI":"10.3389\/fphar.2023.1157135","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:35:46Z","timestamp":1686893746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use"],"prefix":"10.3389","volume":"14","author":[{"given":"Stella","family":"Pesiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafel","family":"Barcelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fradera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/joim.12235","article-title":"Research on drug safety and effectiveness using pharmacoepidemiological databases","volume":"275","author":"Andersen","year":"2014","journal-title":"J. Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.euroneuro.2017.03.002","article-title":"Trends in ADHD medication use in children and adolescents in five Western countries","volume":"27","author":"Bachmann","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0148594","DOI":"10.1371\/journal.pone.0148594","article-title":"Effects of the financial crisis on psychotropic drug consumption in a cohort from a semi-urban region in Catalonia, Spain","volume":"11","author":"Barcel\u00f3","year":"2016","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JCP.0000000000000559","article-title":"Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry","volume":"36","author":"Bra\u00fcner","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0266353","DOI":"10.1371\/journal.pone.0266353","article-title":"Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US","volume":"17","author":"Christiansen","year":"2022","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14740338.5.5.703","article-title":"Off-label and unlicensed prescribing for newborns and children in different settings: A review of the literature and a consideration about drug safety","volume":"5","author":"Cuzzolin","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/YIC.0000000000000216","article-title":"Off-label antidepressant prescription in pediatric outpatients based on China food and drug administration and food and drug administration regulations: A Chinese retrospective study","volume":"33","author":"Deng","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B8","volume-title":"Evidence of harm from off-label or unlicensed medicines in children [Internet]","year":"2004"},{"key":"B9","volume-title":"Paediatric regulation [internet]","year":""},{"key":"B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/cap.2005.15.38","article-title":"Psychotropic co-medication among stimulant-treated children in The Netherlands","volume":"15","author":"Faber","year":"2005","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1517\/14740338.2011.584531","article-title":"Adverse drug reactions in newborns, infants and toddlers: Pediatric pharmacovigilance between present and future","volume":"11","author":"Fabiano","year":"2012","journal-title":"Expert Opin. Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12888-016-0716-x(1)","article-title":"Psychotropic drug use among 0-17 year olds during 2004-2014: A nationwide prescription database study","volume":"16","author":"Hartz","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.aogh.2015.02.004","article-title":"Assessing 15 proposals for promoting innovation and access to medicines globally","volume":"80","author":"Hoffman","year":"2014","journal-title":"Ann. Glob. Health"},{"key":"B14","volume-title":"INEbase [internet]","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/ecp.09.40","article-title":"Challenges in conducting clinical trials in children: Approaches for improving performance","volume":"2","author":"Kern","year":"2009","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/YCO.0b013e328314b776","article-title":"Ethical issues in psychopharmacology of children and adolescents","volume":"21","author":"Koelch","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/jrpp.JRPP_18_42","article-title":"Off-label prescribing of antipsychotics in a Danish child and adolescent mental health center: A register-based study","volume":"7","author":"Korn\u00f8","year":"2018","journal-title":"J. Res. Pharm. Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/cap.2014.0058","article-title":"Psychotropic medication use in French children and adolescents","volume":"25","author":"Kovess Masfety","year":"2015","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2515\/therapie\/2013038","article-title":"Pharmacoepidemiology studies: What levels of evidence and how can they be reached?","volume":"68","author":"Lapeyre-Mestre","year":"2013","journal-title":"Therapies"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2020-000880","article-title":"Does the EU\u2019s paediatric regulation work for new medicines for children in Denmark, Finland, Norway and Sweden? A cross-sectional study","volume":"4","author":"Lepola","year":"2020","journal-title":"BMJ Paediatr. Open"},{"key":"B21","article-title":"Real Decreto 1015\/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales","volume":"174","author":"Ministerio de SanidadPol\u00edtica Social","year":"2009","journal-title":"Bol. Of. del Estado n\u00fam"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-51020-0_5","article-title":"Maintaining the pharmacy model: The Catalan electronic prescription infrastructure","volume-title":"Information infrastructures within European health care: Working with the installed base","author":"Modol","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/00002018-200427130-00006","article-title":"The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients","volume":"27","author":"Neubert","year":"2004","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00787-015-0726-0","article-title":"Psychotropic medicine prescriptions in Italian youths: A multiregional study","volume":"25","author":"Piovani","year":"2016","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00228-012-1265-y","article-title":"The use of medication against attention deficit hyperactivity disorder in Denmark: A drug use study from a national perspective","volume":"68","author":"Potteg\u00e5rd","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1176\/appi.ps.55.9.1049","article-title":"Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths","volume":"55","author":"Safer","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1542\/peds.108.2.e25(2)","article-title":"Psychotropic medication in children: A study from The Netherlands","volume":"108","author":"Schirm","year":"2001","journal-title":"Pediatrics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00044011-200626030-00006","article-title":"Prevalence of methylphenidate use among Israeli children 1998-2004","volume":"26","author":"Vinker","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"B29","volume-title":"Child and adolescent mental and brain health [Internet]","year":"2023"},{"key":"B30","volume-title":"Mental disorders [internet]","year":"2021"},{"key":"B31","volume-title":"Mental health: Strengthening our response [internet]","year":"2018"},{"key":"B32","volume-title":"WHO | Mental health action plan 2013 - 2020 [Internet]","year":"2013"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1753-2000-2-2","article-title":"Prevalence of mental disorders among adolescents in German youth welfare institutions","volume":"2","author":"Zito","year":"2008","journal-title":"Child. Adolesc. Psychiatry Ment. Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/archpedi.157.1.17","article-title":"Psychotropic practice patterns for youth: A 10-year perspective","volume":"157","author":"Zito","year":"2003","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/cap.2009.0003","article-title":"Psychotropic drug use among Icelandic children: A nationwide population-based study","volume":"19","author":"Zo\u00ebga","year":"2009","journal-title":"J. Child. Adolesc. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:35:55Z","timestamp":1686893755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1157135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":35,"alternative-id":["10.3389\/fphar.2023.1157135"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1157135","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1157135"}}